Opioid addiction treatment in United States prisons

Quit Genius Reports Promising Data in Pilot Study of Integrated Digital Alcohol Use Disorder (AUD) Treatment

Retrieved on: 
Monday, December 12, 2022
Cognitive behavioral therapy, Absenteeism, Evidence-based practice, Depression, Liver disease, Naltrexone, Health, Workplace, FDA, AUD, Injury, Opioid addiction treatment in United States prisons, Liver failure, Randomized controlled trial, RCT, Sleep, Telehealth, Opioid, Pharmacy, Risk, Death, Tobacco, WHO, Brain, COVID-19, Nicotine, MAT, Partnership, Mental health, Anxiety, Pharmaceutical industry

NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Quit Genius , the world’s first digital clinic for treating multiple substance addictions, today announced results from a pilot study of integrated alcohol use disorder (AUD) treatment.

Key Points: 
  • NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Quit Genius , the world’s first digital clinic for treating multiple substance addictions, today announced results from a pilot study of integrated alcohol use disorder (AUD) treatment.
  • “The results of this pilot study are certainly promising, with significant decreases in alcohol consumption reported among participants,” said Suzette Glasner, Ph.D., Vice President of Clinical Affairs at Quit Genius.
  • Unfortunately, many suffering won’t seek help; studies indicate that only 1 in 10 people with a substance use disorder gets treatment.
  • The authors found that integrated digital health treatment of AUD combining evidence-based psychosocial and pharmacological treatment is feasible and may produce improvements in both alcohol use and psychiatric symptoms.

Quit Genius Joins the Alight Partner Network with Tobacco Cessation Benefit Offering

Retrieved on: 
Monday, November 14, 2022
Evidence-based practice, Health, Partnership, MAT, Privacy, NYSE, CDC, Pharmacy, Opioid addiction treatment in United States prisons, Tobacco, Quit, Wellness, Nicotine, Growth, Organization, Workplace, Smoking, Express Scripts, Pharmaceutical industry, Alight

NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Quit Genius, the world’s first digital clinic for treating multiple substance addictions, announced today that it has partnered with Alight (NYSE: ALIT), a leading cloud-based provider of integrated digital human capital and business solutions, to provide smoking and vaping cessation through Alight’s proprietary Alight Worklife® platform.

Key Points: 
  • With Quit Genius, Alights clients can offer their employees access to the most clinically validated tobacco cessation solution in the market, with biochemically verified 52% quit rates validated in the largest randomized-controlled trial ever undertaken for a digital tobacco cessation program.
  • Having Quit Genius as part of Alights Partner Network enables stronger utilization due to the employee experience the Alight Worklife platform provides.
  • The Quit Genius tobacco cessation program provides a tech-enabled digital clinic designed to help members access evidence-based care wherever they are while helping employers save on healthcare costs.
  • To-date, Quit Genius has helped more than 750,000 people improve their lives and quit their addictions.

Alight Expands Holistic Wellbeing Solutions with the Addition of Hinge Health and Quit Genius to Partner Network

Retrieved on: 
Monday, November 14, 2022
Technology, Tobacco, Professional Services, Health, General Health, Wearables, Mobile Technology, Retail, Data Analytics, Software, Human Resources, Telemedicine, Virtual Medicine, Workforce, Evidence-based practice, Human, Digital, Microsoft Partner Network, MAT, NYSE, Pharmacy, Opioid addiction treatment in United States prisons, Physician, Nicotine, MSK, Ecosystem, Growth, Organization, Health, Therapy, Workplace, Video game, Pharmaceutical industry, Medicine, Alight

As part of our partner network, Hinge Health and Quit Genius offer the support and resources todays workers need to address specific care needs while helping employers reduce medical costs through caring for specific conditions.

Key Points: 
  • As part of our partner network, Hinge Health and Quit Genius offer the support and resources todays workers need to address specific care needs while helping employers reduce medical costs through caring for specific conditions.
  • Hinge Health believes that building curated ecosystems, bringing together best-of-breed solutions, can significantly improve the healthcare experience for clients and members, said Jim Pursley, president, Hinge Health.
  • Adding Quit Genius to Alight's integrated benefits solutions is a great fit for both our organizations," said Yusuf Sherwani, M.D., co-founder and CEO of Quit Genius.
  • To learn more about Alights Partner Network, visit Alight.com
    Hinge Health is building the worlds most patient-centered Digital Musculoskeletal (MSK) Clinic.

Acadia Healthcare Set to Open Four New Comprehensive Treatment Centers

Retrieved on: 
Tuesday, November 8, 2022
General Health, Health, Mental Health, Buprenorphine, Opioid addiction treatment in United States prisons, Patient, CTC, State, Health care, Chinese, The Sundays, Brand New, MAT, Acadia Healthcare, Heroin, Methadone, Dignity, Multimedia, Bed, Hospital, Pharmaceutical industry

Acadia Healthcare, a leading provider of behavioral healthcare services, is accepting new patients at its four new Comprehensive Treatment Centers (CTCs) in Georgia.

Key Points: 
  • Acadia Healthcare, a leading provider of behavioral healthcare services, is accepting new patients at its four new Comprehensive Treatment Centers (CTCs) in Georgia.
  • View the full release here: https://www.businesswire.com/news/home/20221107006188/en/
    Acadia recently acquired the four CTCs from Georgia-based Brand New Start Treatment Centers.
  • The four outpatient treatment centers, which are all located within 40 miles of Atlanta, are:
    We are excited to have the opportunity to play a critical role in ending the opioid epidemic in our community, said Erin McCarthy, regional vice president of Comprehensive Treatment Centers.
  • With more than 22,500 employees serving approximately 70,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

DESPITE INCREASING ACCESS, WOMEN STILL CRAVE MORE CANNABIS EDUCATION, ACCORDING TO NATIONAL SURVEY

Retrieved on: 
Monday, October 24, 2022
Method, Cannabis, Growth, Woman, Post-traumatic stress disorder, Education, Menopause, Sleep, Multimedia, Drinking, Wine, Generation Z, Knowledge, Learning, ACHES, Health, Gen, Glass, Pains, Opioid addiction treatment in United States prisons, Adult, Weight gain, Research, Anxiety, Chronic pain, PTSD, Nervous system, Drug, Soft drink

ELLICOTT CITY, Md., Oct. 24, 2022 /PRNewswire/ -- As more states legalize cannabis, it's no surprise that 62 percent of women in the U.S. say they're cannabis curious, according to a new survey from Blissiva, makers of a line of doctor-formulated cannabis-infused products designed for women. The survey, which was conducted in October 2022 among more than 1,000 American women, reveals that while women are interested in learning about the health benefits of using cannabis, they are more open to using cannabis if it's recommended by a doctor.  

Key Points: 
  • More than 6 out of 10 (62%) of women say they're cannabis curious, with millennial women (74%) being the most often to express curiosity compared to other generational cohorts.
  • Although the majority of adult women of every age expressed as well (Gen Z women: 61%; Gen X: 62%; baby boomers: 52%).
  • More than half of women (52%) are interested in cannabis as a solution to anxiety and mental health issues.
  • Just over half (55%) of women are interested in using cannabis to provide relief from aches and pains.

Quit Genius Selected for Evernorth Digital Health Formulary to Provide Alcohol and Opioid Use Disorder Care

Retrieved on: 
Thursday, September 15, 2022
Nicotine, Opioid addiction treatment in United States prisons, Opioid use disorder, Formulary, COVID, Program, Mental health, Patient, CEO, Liver failure, Evidence-based practice, Â, Solution, Tobacco, Workplace, MAT, Randomized controlled trial, Digital health, Pharmacy, GLOBE, Health insurance, Pharmaceutical industry

These solutions are in addition to Quit Genius tobacco use disorder care solution, which was added to the Formulary in 2019, and rounds out a suite of substance use disorder care.

Key Points: 
  • These solutions are in addition to Quit Genius tobacco use disorder care solution, which was added to the Formulary in 2019, and rounds out a suite of substance use disorder care.
  • Weve expanded our digital clinic to offer solutions for tobacco, alcohol and opioid addictions, as we strongly believe employers and health payers need an end-to-end solution for multiple addictions focused on the continuum of addiction care.
  • To meet this urgent need and give employers an affordable healthcare benefit that provides broader access and better care for employees, Quit Genius now offers care for alcohol and opioid addictions.
  • Quit Genius is the worlds first digital clinic for treating nicotine, alcohol and opioid addictions.

New Survey Shows Remote Work Has Fueled Increased Drug Use

Retrieved on: 
Wednesday, August 31, 2022
Drug overdose, CEO, Female, Tobacco, Solution, MAT, Death, Awareness, Randomized controlled trial, Male, Method, Quit, Evidence-based practice, Confidentiality, Opioid use disorder, GLOBE, Workplace, Privacy, Opioid, Pharmacy, Opioid addiction treatment in United States prisons, Health insurance, Drug, Pharmaceutical industry

The survey of 1,000+ American workers was conducted by Quit Genius , which has launched the nations first digital clinic for opioid addiction.

Key Points: 
  • The survey of 1,000+ American workers was conducted by Quit Genius , which has launched the nations first digital clinic for opioid addiction.
  • The survey, conducted in July 2022, explored remote work, drug and alcohol use, and barriers to access to employer-provided addiction treatment programs.
  • Male remote workers were 1.4 times more likely than female remote workers to report being impaired by drugs and/or alcohol at work.
  • Similarly, 20 percent of respondents - 1 in 5 - said that drug and/or alcohol use has impacted their work performance.

Wilmington Treatment Center Named Top Addiction Treatment Center in North Carolina

Retrieved on: 
Thursday, August 25, 2022
Research, Accreditation, Statista, Veteran, Addiction, Desert Hope Addiction Treatment Center, No, GLOBE, Population, Substance Abuse and Mental Health Services Administration, Opioid addiction treatment in United States prisons, Substance Abuse, SAMHSA, Pharmaceutical industry, Newsweek

WILMINGTON, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Wilmington Treatment Center is proud to announce that it ranked No.

Key Points: 
  • WILMINGTON, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Wilmington Treatment Center is proud to announce that it ranked No.
  • 1 on Newsweeks list of best addiction treatment centers in North Carolina for 2022.
  • 1 addiction treatment center in North Carolina, said Wilmington Treatment Center CEO Robert Pitts.
  • Wilmington Treatment Center, located in Wilmington, North Carolina, is a highly respected provider of treatment for adults age 18 and older who are struggling with addictions and co-occurring mental health concerns.

Quit Genius Becomes The First Substance Use Disorder Treatment Provider To Put 100% of Fees at Risk, Guaranteeing Performance and Value For Virtual Addiction Treatment

Retrieved on: 
Wednesday, July 13, 2022
Opioid addiction treatment in United States prisons, Method, GLOBE, MAT, SUD, Randomized controlled trial, Evidence-based practice, Opioid, Nicotine, Pharmacy, Risk, Workplace, Program, CEO, Pharmaceutical industry, Health insurance

Quit Genius, which sells to employers and health plans, is the first provider in its category to move to a fully at-risk pricing model.

Key Points: 
  • Quit Genius, which sells to employers and health plans, is the first provider in its category to move to a fully at-risk pricing model.
  • Previously, Quit Genius offered 50 percent fees at risk, alongside a bundled case rate fee.
  • Now, if Quit Genius misses performance goals, clients are eligible to receive up to 100 percent of the total fees paid.
  • Performance guarantees are measured annually, but clients also receive quarterly performance updates to measure whether Quit Genius is on-track to meet them.

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

Retrieved on: 
Tuesday, June 7, 2022
Eleazar Sukenik, MEAI, CSE, Research, Cocaine, News, Opioid addiction treatment in United States prisons, Gonda, Laboratory rat, Rat, Therapy, Male, GLOBE, Acquisition, CPP, Conditioned place preference, FSE, OTC Markets Group, Bar-Ilan University, Hebrew University of Jerusalem, Pharmaceutical industry, Drug

VANCOUVER, June 07, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.

Key Points: 
  • VANCOUVER, June 07, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (Clearmind or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.
  • While effective treatments for opioid addictions have been available, this could be the first dedicated treatment for cocaine addiction, which is a global crisis.
  • Rats previously conditioned with cocaine received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg.
  • The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction.